Arteriocyte to Accelerate Production of Nanofiber-Based Technology for Use in Clinical Research

Arteriocyte received a grant of $1 million from the Third Frontier Commission of the Ohio Department of Development to speed up manufacturing using Good Manufacturing practices (GMP), the company’s NANEX technology for clinical purposes under the brand HemaEx.

The NANEX technology is a three-dimensional nanofiber-based scaffold developed to imitate the bone marrow. It develops a quick ex vivo method to proliferate hematopoietic stem cells associated by least differentiation. This technology received license from John Hopkins University to improve stem cell treatments in order to cure cancer and cardiovascular diseases.

Arteriocyte introduced the technology commercially for research purposes in December 2010. This kit allows scientists to quickly expand HSCs to perform preclinical research. The company utilizes the grant to quickly upgrade its NANEX production plant to produce HemaEx culture ware which is "clinic-ready" and complies with GMP standards.

The company might work with the Ohio State University’s clinical partners to authenticate the use of HemaEx while conducting therapies to cure blood cancer. Arteriocyte is anticipated to continue its collaboration with Miltenyi Biotec to develop media additives that meets GMP standards and hence safe for human consumption. The company will soon release a GMP NANEX product for use in clinical research. It will also request regulatory approval to enable manufacturing of clinical cell therapy by 2013.